Regional CRO strengthens position in pharma and biotech through acquisition

Regional clinical research organisation (CRO), Optimapharm, has acquired the Czech company MKS Research to strengthen its portfolio of clients in the pharma and biotech industries.

This acquisition is in line with Optimapharm’s medium-term strategic objective of becoming the largest independent CRO in Central and Eastern Europe (CEE). Through the consolidation of MKS Research, the company will have a total of 120 full-time employees and annual revenues over €12 million.

“The clinical research market is experiencing a continued rise, and we have the knowhow, references and strong financial position enabling us to lead the consolidation in the region. Moreover, our ambition is to double our revenues over the next three years, and continue acquiring good-quality companies such as MKS Research,” explained Optimapharm CEO Gordana Gregurić Čičak.

“We are becoming a part of a much larger company with structured operational support,” stated MKS Research executive director Veronika Sebkova. “This means that we will be even better able to focus on projects and growth in the Czech and Slovak markets, while our employees will get new opportunities to develop their careers within an international group and work on more complex projects.”